Dr. Samer S. Kasbari
Claim this profileSoutheastern Medical Oncology Center-Clinton
Expert in Cancer
Expert in Adenocarcinoma
72 reported clinical trials
132 drugs studied
Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage I
2Adenocarcinoma
Global LeaderStage IV
Stage III
BRCA1 positive
Affiliated Hospitals
Clinical Trials Samer S. Kasbari is currently running
BRAF-Targeted Therapy
for Colon Cancer
This phase II/III trial compares treatment with encorafenib and cetuximab to usual care (patient observation) for reducing the chance of cancer recurrence after standard surgery and chemotherapy in patients with BRAF-mutated stage IIB-III colon cancer. Encorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Cetuximab is in a class of medications called monoclonal antibodies. It binds to a protein called EGFR, which is found on some types of tumor cells. This may help keep tumor cells from growing. Giving encorafenib and cetuximab after standard surgery and chemotherapy may be more effective at reducing the chance of cancer recurrence compared to the usual patient observation.
Recruiting1 award Phase 2 & 3
Osimertinib + Bevacizumab
for Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting2 awards Phase 331 criteria
More about Samer S. Kasbari
Clinical Trial Related5 years of experience running clinical trials · Led 72 trials as a Principal Investigator · 39 Active Clinical TrialsTreatments Samer S. Kasbari has experience with
- Nivolumab
- Carboplatin
- Atezolizumab
- Paclitaxel
- Pembrolizumab
- Cisplatin
Breakdown of trials Samer S. Kasbari has run
Cancer
Adenocarcinoma
Breast Cancer
Tumors
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Samer S. Kasbari specialize in?
Samer S. Kasbari focuses on Cancer and Adenocarcinoma. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are Stage III.
Is Samer S. Kasbari currently recruiting for clinical trials?
Yes, Samer S. Kasbari is currently recruiting for 38 clinical trials in Clinton North Carolina. If you're interested in participating, you should apply.
Are there any treatments that Samer S. Kasbari has studied deeply?
Yes, Samer S. Kasbari has studied treatments such as Nivolumab, Carboplatin, Atezolizumab.
What is the best way to schedule an appointment with Samer S. Kasbari?
Apply for one of the trials that Samer S. Kasbari is conducting.
What is the office address of Samer S. Kasbari?
The office of Samer S. Kasbari is located at: Southeastern Medical Oncology Center-Clinton, Clinton, North Carolina 28328 United States. This is the address for their practice at the Southeastern Medical Oncology Center-Clinton.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.